JP7517702B2 - Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体 - Google Patents

Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体 Download PDF

Info

Publication number
JP7517702B2
JP7517702B2 JP2021514423A JP2021514423A JP7517702B2 JP 7517702 B2 JP7517702 B2 JP 7517702B2 JP 2021514423 A JP2021514423 A JP 2021514423A JP 2021514423 A JP2021514423 A JP 2021514423A JP 7517702 B2 JP7517702 B2 JP 7517702B2
Authority
JP
Japan
Prior art keywords
nlrp3
antibody
seq
modulator
nlrp3 inflammasome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021514423A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500457A (ja
Inventor
マクギリガン，ヴィクトリア
Original Assignee
ユニバーシティ オブ アルスター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ アルスター filed Critical ユニバーシティ オブ アルスター
Publication of JP2022500457A publication Critical patent/JP2022500457A/ja
Priority to JP2024104327A priority Critical patent/JP2024125385A/ja
Application granted granted Critical
Publication of JP7517702B2 publication Critical patent/JP7517702B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021514423A 2018-09-14 2019-09-16 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体 Active JP7517702B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024104327A JP2024125385A (ja) 2018-09-14 2024-06-27 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1815045.8 2018-09-14
GBGB1815045.8A GB201815045D0 (en) 2018-09-14 2018-09-14 Bispecific antibody targeting IL-1R1 and NLPR3
PCT/EP2019/074745 WO2020053447A1 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting il-1r1 and nlpr3

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024104327A Division JP2024125385A (ja) 2018-09-14 2024-06-27 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体

Publications (2)

Publication Number Publication Date
JP2022500457A JP2022500457A (ja) 2022-01-04
JP7517702B2 true JP7517702B2 (ja) 2024-07-17

Family

ID=64013420

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021514423A Active JP7517702B2 (ja) 2018-09-14 2019-09-16 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
JP2021514418A Active JP7645544B2 (ja) 2018-09-14 2019-09-16 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
JP2024104327A Pending JP2024125385A (ja) 2018-09-14 2024-06-27 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021514418A Active JP7645544B2 (ja) 2018-09-14 2019-09-16 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
JP2024104327A Pending JP2024125385A (ja) 2018-09-14 2024-06-27 Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体

Country Status (7)

Country Link
US (2) US12264201B2 (enExample)
EP (2) EP3849662A1 (enExample)
JP (3) JP7517702B2 (enExample)
CN (2) CN112996564A (enExample)
AU (2) AU2019338955B2 (enExample)
GB (1) GB201815045D0 (enExample)
WO (2) WO2020053446A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
JP2024501033A (ja) * 2020-12-28 2024-01-10 エムディー ヘルスケア インコーポレイテッド ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物
US20250382341A1 (en) * 2022-12-30 2025-12-18 The Regents Of The University Of California Methods and compositions of in vivo engineering of t-cells to anti-inflammatory cells and therapeutic applications there of
CN119925593B (zh) * 2023-06-05 2025-11-25 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂
CN120535628B (zh) * 2023-06-05 2025-11-25 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的纯化方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170841A1 (en) 2000-02-17 2003-09-11 Millennium Pharmaceuticals, Inc., A Delaware Corporation Novel molecules of the pyrin domain protein family and uses thereof
JP2012508005A (ja) 2008-11-07 2012-04-05 メディミューン リミテッド Ｉｌ−１ｒ１に対する結合構成要素
JP2013537539A (ja) 2010-08-13 2013-10-03 ジェネンテック， インコーポレイテッド 疾患の治療のためのＩＬ−１β及びＩＬ−１８に対する抗体
JP2017502064A (ja) 2014-01-10 2017-01-19 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
WO2017079352A2 (en) 2015-11-04 2017-05-11 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296333A1 (en) 2000-09-26 2002-04-08 The Burnham Institute Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
US20080008652A1 (en) 2006-01-10 2008-01-10 The Regents Of The University Of Michigan Methods and compositions for mediation of immune responses and adjuvant activity
FR2937339B1 (fr) 2008-10-21 2013-02-15 Univ Bourgogne Procede de detection de la maladie atheromateuse.
WO2011109459A2 (en) 2010-03-04 2011-09-09 University Of Miami Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases
US9707272B2 (en) * 2011-07-12 2017-07-18 Universitat Zurich Method for the treatment of acne by administering IL-1β antibody
US10633451B2 (en) * 2012-02-03 2020-04-28 Hoffmann-La Roche Inc. Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
EP2812697B1 (en) 2012-02-06 2017-03-22 University of Miami Innate immune proteins as biomarkers for cns injury
EP2825561A4 (en) 2012-03-15 2016-03-09 Permeon Biolog Inc CELL PENETRATING COMPOSITIONS FOR THE DISPOSAL OF INTRA-CELLULAR ANTIBODIES AND ANTIBODY-RELATED UNITS AND METHODS OF USE
US20160354437A1 (en) * 2014-02-13 2016-12-08 Northwestern University Compositions and methods for modulation of immune response
CN104258398B (zh) * 2014-10-14 2017-12-22 中国科学技术大学 Drd1及其激动剂在制备治疗nlrp3炎症小体相关炎症性疾病药物中的用途
JP2019069905A (ja) * 2016-02-29 2019-05-09 国立大学法人大阪大学 組織損傷治療剤
US20200115358A1 (en) * 2016-03-11 2020-04-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin and icaritin derivatives
WO2018022982A1 (en) * 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030170841A1 (en) 2000-02-17 2003-09-11 Millennium Pharmaceuticals, Inc., A Delaware Corporation Novel molecules of the pyrin domain protein family and uses thereof
JP2012508005A (ja) 2008-11-07 2012-04-05 メディミューン リミテッド Ｉｌ−１ｒ１に対する結合構成要素
JP2013537539A (ja) 2010-08-13 2013-10-03 ジェネンテック， インコーポレイテッド 疾患の治療のためのＩＬ−１β及びＩＬ−１８に対する抗体
JP2017502064A (ja) 2014-01-10 2017-01-19 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
WO2017079352A2 (en) 2015-11-04 2017-05-11 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jurg Tschopp，NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?，Nat Rev Immunol，2010年，10，210-5

Also Published As

Publication number Publication date
JP2024125385A (ja) 2024-09-18
AU2019338955B2 (en) 2026-03-19
EP3849661A1 (en) 2021-07-21
AU2019338674A1 (en) 2021-04-22
US12227579B2 (en) 2025-02-18
AU2019338955A1 (en) 2021-04-15
JP2022500457A (ja) 2022-01-04
US20220041739A1 (en) 2022-02-10
US20220033507A1 (en) 2022-02-03
GB201815045D0 (en) 2018-10-31
JP2022500455A (ja) 2022-01-04
CN112996564A (zh) 2021-06-18
WO2020053446A1 (en) 2020-03-19
CN112996563A (zh) 2021-06-18
AU2019338674B2 (en) 2026-02-05
EP3849662A1 (en) 2021-07-21
JP7645544B2 (ja) 2025-03-14
WO2020053447A1 (en) 2020-03-19
US12264201B2 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
JP7517702B2 (ja) Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
JP7258366B2 (ja) トランスサイレチン（ｔｔｒ）アミロイドーシスに対する抗体療法及びそのためのヒト由来抗体
JP7564853B2 (ja) 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法
JP7036860B2 (ja) 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
JP2023159314A (ja) マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
TWI747922B (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
RU2727911C2 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JP7352973B2 (ja) 二重特異性抗体及びその使用
JP6907124B2 (ja) Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物
IL270239B1 (en) Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
IL321314A (en) Low ph pharmaceutical composition comprising t cell engaging antibody constructs
JP2020506954A (ja) 眼疾患の治療のための過リン酸化タウに特異的な抗体
CA3200317A1 (en) Multitargeting bispecific antigen-binding molecules of increased selectivity
JP6475225B2 (ja) 治療上の使用のための抗ｂａｇ３抗体
TW202208434A (zh) Mageb2結合構建體
IL301926A (en) Antigen binding domain with reduced clipping rate
CN106029092B (zh) 能够溶解带有膜锚定型免疫球蛋白a的b淋巴球与降低免疫球蛋白a生产的抗人类膜锚定型免疫球蛋白a抗体
US20220372159A1 (en) Treatment and Prevention of Ischemic Diseases And/Or Ischemic Tissue Damages
HK40022840B (zh) 抗α-突触核蛋白抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230823

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240627

R150 Certificate of patent or registration of utility model

Ref document number: 7517702

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150